Gilead completes acquisition of Pharmasset

Pharmasset becomes wholly owned subsidiary of Gilead

FOSTER CITY, Calif. — Drug maker Gilead Sciences has completed its $11.2 billion acquisition of Pharmasset, Gilead said.

The $137-per-share merger, originally announced in November 2011, makes Pharmasset a wholly owned subsidiary of Gilead. Pharmasset, based in Princeton, N.J., focuses on developing orally administered drugs for viral infections, particularly hepatitis C.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.